Title:
The biomarker for predicting and evaluating the reactivity for [for / to a Libertinib compound / a thyroid cancer] a renal cancer
Document Type and Number:
Japanese Patent JP6038128
Kind Code:
B2
Abstract:
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
Inventors:
Yasuhiro Funabashi
Masashi Kadowaki
Junji Matsui
Simon Jason S.
Shu, Lucy
Masashi Kadowaki
Junji Matsui
Simon Jason S.
Shu, Lucy
Application Number:
JP2014513691A
Publication Date:
December 07, 2016
Filing Date:
May 31, 2012
Export Citation:
Assignee:
Eisai R & D Management Co., Ltd.
International Classes:
C12Q1/68; C12N15/09; G01N33/68
Foreign References:
| WO2010048304A1 |
Other References:
Clin. Cancer Res.,2011年 4月,Vol.17,No.8,,p2528-2537
Annals of Oncology,2011年 4月,Vol.23,p46-52
Annals of Oncology,2011年 4月,Vol.23,p46-52
Attorney, Agent or Firm:
Yoshiki Hasegawa
Yoshinori Shimizu
Kimoto
Yoshinori Shimizu
Kimoto
Previous Patent: The control device for resource assignment
Next Patent: CONNECTION OF THICK PLASTIC SHEET
Next Patent: CONNECTION OF THICK PLASTIC SHEET